Zydus Lifesciences Limited has entered into a licensing and supply agreement with Lupin Limited to co-market an innovative Semaglutide Injection in India, marking a significant step toward improving access to advanced treatments for diabetes and weight management.
The partnership brings together Zydus’ product development expertise and Lupin’s strong distribution network, with a shared focus on addressing the growing burden of metabolic disorders in India.
Key Highlights of the Partnership
- Zydus will market the drug under the brand names SEMAGLYN, MASHEMA, and ALTERMET
- Lupin will co-market under Semanext and Lupin’s Livarise
- The agreement includes upfront licensing fees and milestone-based payments from Lupin to Zydus
- The therapy will be delivered via a patient-friendly reusable pen device
Under the terms of the agreement, Lupin will receive semi-exclusive rights to co-market the product in India, enabling broader reach and improved patient access.
Focus on Patient Convenience and Access
The Semaglutide Injection, available in a 15 mg/3 ml format, is designed to simplify administration and improve adherence through its reusable pen device. This is expected to enhance convenience for patients managing long-term metabolic conditions.
Speaking on the collaboration, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said:
“Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients’ needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India.”
Nilesh Gupta, Managing Director, Lupin, added:
“Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India.”
Indications and Use
Semaglutide is indicated for adults with insufficiently controlled type 2 diabetes mellitus, used alongside diet and exercise:
- As monotherapy when metformin is not suitable due to intolerance or contraindications
- In combination with other diabetes medications
It is also approved for chronic weight management in adults:
- With a BMI of 30 or higher (obesity)
- Or BMI of 27 or higher (overweight) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia
What This Means for Runners and Fitness Enthusiasts
For runners and those on a fitness journey, the growing availability of therapies like Semaglutide signals a shift in how weight management and metabolic health are being approached in India. While consistent training, balanced nutrition and recovery remain the foundation of performance, some individuals struggling with obesity or metabolic conditions may benefit from medically guided interventions. Improved access to such treatments can help certain individuals reach a healthier baseline, making it easier to begin or sustain endurance activities like running. That said, these therapies are not performance enhancers and should only be used under medical supervision as part of a broader, sustainable lifestyle approach.
